Analysis of vesicles-associated nucleic acids for BRAF, KRAS, and EGFR mutations has shown higher sensitivity compared to plasma ctDNA in non-small cell lung cancer (NSCLC) patients (13). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.